- Home
- LRN vs IONS Comparison
LRN vs IONS Comparison
Compare LRN & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRN
- IONS
- Stock Information
- Founded
- LRN 2000
- IONS 1989
- Country
- LRN United States
- IONS United States
- Employees
- LRN N/A
- IONS N/A
- Industry
- LRN Other Consumer Services
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- LRN Real Estate
- IONS Health Care
- Exchange
- LRN Nasdaq
- IONS Nasdaq
- Market Cap
- LRN 5.4B
- IONS 6.0B
- IPO Year
- LRN 2007
- IONS 1991
- Fundamental
- Price
- LRN $119.60
- IONS $33.72
- Analyst Decision
- LRN Buy
- IONS Buy
- Analyst Count
- LRN 5
- IONS 18
- Target Price
- LRN $124.40
- IONS $60.63
- AVG Volume (30 Days)
- LRN 747.5K
- IONS 1.8M
- Earning Date
- LRN 04-22-2025
- IONS 05-06-2025
- Dividend Yield
- LRN N/A
- IONS N/A
- EPS Growth
- LRN 50.08
- IONS N/A
- EPS
- LRN 5.95
- IONS N/A
- Revenue
- LRN $2,193,315,000.00
- IONS $705,138,000.00
- Revenue This Year
- LRN $15.83
- IONS N/A
- Revenue Next Year
- LRN $6.94
- IONS $25.98
- P/E Ratio
- LRN $20.08
- IONS N/A
- Revenue Growth
- LRN 13.13
- IONS N/A
- 52 Week Low
- LRN $56.17
- IONS $30.23
- 52 Week High
- LRN $145.00
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- LRN 32.19
- IONS 51.47
- Support Level
- LRN $112.28
- IONS $31.99
- Resistance Level
- LRN $142.13
- IONS $35.00
- Average True Range (ATR)
- LRN 5.45
- IONS 1.48
- MACD
- LRN -2.92
- IONS 0.19
- Stochastic Oscillator
- LRN 23.82
- IONS 52.42
About LRN Stride Inc.
Stride Inc is an American online educational company. It offers alternative programs to traditional on-campus schooling. It also operates state-funded virtual charter schools around the United States. The educational programs for K-12 students are usually monitored by parents and provide virtual classroom environments where teachers meet with students online, by phone, or in-person. The company's contractual agreements with various school districts to offer its curriculum programs provide a majority of the company's revenue. The company lines of business are Managed Public School Programs, Institutional, and Private Pay Schools and Other.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.